Clinical trial
Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer
NCT00286819 · Central European Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00286819 |
|---|---|
| Title | Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer |
| Official title | Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin 75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin 90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast Cancer |
| Lead sponsor | Central European Cooperative Oncology Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | the FEC75 and 95 regimen |
| Enrollment | 50 |
| Start date | Apr 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Feb 6, 2006 |
| Last update posted | May 16, 2012 |
| Countries | Austria, Hungary, Poland, Slovakia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: